Advertisement
Canada markets close in 6 hours 1 minute

  • S&P/TSX

    21,977.03
    -34.69 (-0.16%)
     

  • S&P 500

    5,077.98
    +7.43 (+0.15%)
     

  • DOW

    38,472.78
    -30.91 (-0.08%)
     

  • CAD/USD

    0.7296
    -0.0024 (-0.33%)
     

  • CRUDE OIL

    82.80
    -0.56 (-0.67%)
     

  • Bitcoin CAD

    90,337.91
    -818.23 (-0.90%)
     

  • CMC Crypto 200

    1,430.32
    +6.22 (+0.44%)
     

  • GOLD FUTURES

    2,332.20
    -9.90 (-0.42%)
     

  • RUSSELL 2000

    2,004.14
    +1.49 (+0.07%)
     

  • 10-Yr Bond

    4.6420
    +0.0440 (+0.96%)
     

  • NASDAQ

    15,791.68
    +95.04 (+0.61%)
     

  • VOLATILITY

    15.71
    +0.02 (+0.13%)
     

  • FTSE

    8,068.94
    +24.13 (+0.30%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6822
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS OPEN MIXED, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Novartis wins FDA's breakthrough tag for lung cancer hopeful

Reuters
Updated
FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

ZURICH (Reuters) - Novartis <NOVN.S> has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a form of the disease for which there are no targeted therapies now, the Basel-based company said on Friday.

(This story fixes typographical error in first paragraph.)

(Reporting by John Miller; Editing by Michael Shields and David Goodman)